饮食诱导的非酒精性脂肪性肝病小鼠模型研究进展

摘要/Abstract

摘要： 非酒精性脂肪性肝病(NAFLD)已成为影响人类健康的主要肝病,但其病因和发病机制迄今尚未被完全阐明,也仍然缺乏有效治疗药物。能够模拟NAFLD临床表型和病理过程的动物模型是探讨其复杂的病理机制和发展新型诊疗方法的必要研究工具。啮齿类动物的肝脏结构和功能与人类相似,并且容易管理和繁殖,被广泛应用于NAFLD造模,其模型建立主要通过饮食调整、化学物质刺激或基因编辑等方式诱导。其中,饮食诱导小鼠NAFLD模型的生物学机制、发展过程和表型与人类NAFLD相近,近年来发展迅速,应用最为广泛。但饮食成分组成、诱导时间、小鼠年龄和性别等多种因素均会对模型造成影响。目前尚缺乏统一规范的NAFLD模型制备流程。本文汇总近年来研究报道的饮食诱导的小鼠NAFLD模型,分析和讨论不同模型的特性及优缺点,以期为选择恰当的小鼠模型进行NAFLD研究提供指导和依据。

关键词: 非酒精性脂肪性肝病, 动物模型, 小鼠, 饮食

丁俊瑶, 柳涛, 杨丽丽, 宋海燕, 郑培永. 饮食诱导的非酒精性脂肪性肝病小鼠模型研究进展[J]. 肝脏, 2025, 30(10): 1430-1434.

/ 推荐

参考文献

[1] Lazarus J V, Mark H E, Anstee Q M, et al. Advancing the global public health agenda for NAFLD: a consensus statement[J]. Nat Rev Gastroenterol Hepatol, 2022,19(1):60-78.
[2] 中华医学会肝病学分会. 代谢相关(非酒精性)脂肪性肝病防治指南(2024年版)[J]. 中华肝脏病杂志, 2024,32(5):418-434.
[3] Flessa C M, Nasiri-Ansari N, Kyrou I, et al. Genetic and diet-induced animal models for non-alcoholic fatty liver disease (NAFLD) research[J]. Int J Mol Sci, 2022,23(24):15791.
[4] Denk H, Abuja P M, Zatloukal K. Animal models of NAFLD from the pathologist's point of view[J]. Biochim Biophys Acta Mol Basis Dis, 2019,1865(5):929-942.
[5] Recena Aydos L, Aparecida do Amaral L, Serafim de Souza R, et al. Nonalcoholic fatty liver disease induced by high-fat diet in c57bl/6 models[J]. Nutrients, 2019,11(12):3067.
[6] Hu S, Wang L, Yang D, et al. Dietary fat, but not protein or carbohydrate, regulates energy intake and causes adiposity in mice[J]. Cell Metab, 2018,28(3):415-431.
[7] Rahmadi M, Nurhan A D, Pratiwi E D, et al. The effect of various high-fat diet on liver histology in the development of NAFLD models in mice[J]. J Basic Clin Physiol Pharmacol, 2021,32(4):547-553.
[8] Saxena R, Nassiri M, Yin X M, et al. Insights from a high-fat diet fed mouse model with a humanized liver[J]. Plos One, 2022,17(5):e268260.
[9] Chen K, Ma J, Jia X, et al. Advancing the understanding of NAFLD to hepatocellular carcinoma development: from experimental models to humans[J]. Biochim Biophys Acta Rev Cancer, 2019,1871(1):117-125.
[10] Zhi S, Congcong Z, Zhiling G, et al. Quantitative proteomics of HFD-induced fatty liver uncovers novel transcription factors of lipid metabolism[J]. Int J Biol Sci, 2022,18(8):3298-3312.
[11] Li Y, Liu Y, Chen Z, et al. Protopanaxadiol ameliorates NAFLD by regulating hepatocyte lipid metabolism through AMPK/SIRT1 signaling pathway[J]. Biomed Pharmacother, 2023,160:114319.
[12] Velázquez K T, Enos R T, Bader J E, et al. Prolonged high-fat-diet feeding promotes non-alcoholic fatty liver disease and alters gut microbiota in mice[J]. World J Hepatol, 2019,11(8):619-637.
[13] Febbraio M A, Reibe S, Shalapour S, et al. Preclinical models for studying NASH-driven HCC: how useful are they?[J]. Cell Metab, 2019,29(1):18-26.
[14] Lodge M, Dykes R, Kennedy A. Regulation of fructose metabolism in nonalcoholic fatty liver disease[J]. Biomolecules, 2024,14(7):845
[15] Herman M A, Birnbaum M J. Molecular aspects of fructose metabolism and metabolic disease[J]. Cell Metab, 2021,33(12):2329-2354.
[16] Zhao S, Jang C, Liu J, et al. Dietary fructose feeds hepatic lipogenesis via microbiota-derived acetate[J]. Nature, 2020,579(7800):586-591.
[17] Silva-Veiga F M, Miranda C S, Martins F F, et al. Gut-liver axis modulation in fructose-fed mice: a role for PPAR-α and linagliptin[J]. J Endocrinol, 2020,247(1):11-24.
[18] Oliveira-Cordeiro B, Fernandes-DA-Silva A, Silva-Veiga F M, et al. Long-term hepatic damage in high-fructose-fed c57bl/6 mice: hepatic fibrogenesis, endoplasmic reticulum stress markers, and fibrosis[J]. An Acad Bras Cienc, 2023,95(suppl 2):e20220784.
[19] Im Y R, Hunter H, de Gracia Hahn D, et al. A systematic review of animal models of NAFLD finds high-fat, high-fructose diets most closely resemble human NAFLD[J]. Hepatology, 2021,74(4):1884-1901.
[20] Chiang Morales M D, Chang C Y, Le V L, et al. High-fructose/high-fat diet downregulates the hepatic mitochondrial oxidative phosphorylation pathway in mice compared with high-fat diet alone[J]. Cells, 2022,11(21):3425
[21] Mock K, Lateef S, Benedito V A, et al. High-fructose corn syrup-55 consumption alters hepatic lipid metabolism and promotes triglyceride accumulation[J]. J Nutr Biochem, 2017,39:32-39.
[22] Luo Y, Woodie L N, Graff E C, et al. Role of liquid fructose/sucrose in regulating the hepatic transcriptome in a high-fat western diet model of NAFLD[J]. J Nutr Biochem, 2023,112:109174.
[23] Dong Y, Li W, Yin J. The intestinal-hepatic axis: a comprehensive review on fructose metabolism and its association with mortality and chronic metabolic diseases[J]. Crit Rev Food Sci Nutr, 2023:1-14.
[24] Venkatesan N, Doskey L C, Malhi H. The role of endoplasmic reticulum in lipotoxicity during metabolic dysfunction-associated steatotic liver disease (MASLD) pathogenesis[J]. Am J Pathol, 2023,193(12):1887-1899.
[25] Savard C, Tartaglione E V, Kuver R, et al. Synergistic interaction of dietary cholesterol and dietary fat in inducing experimental steatohepatitis[J]. Hepatology, 2013,57(1):81-92.
[26] Gao X, Lin X, Xin Y, et al. Dietary cholesterol drives the development of nonalcoholic steatohepatitis by altering gut microbiota mediated bile acid metabolism in high-fat diet fed mice[J]. J Nutr Biochem, 2023,117:109347.
[27] Zhang X, Coker O O, Chu E S, et al. Dietary cholesterol drives fatty liver-associated liver cancer by modulating gut microbiota and metabolites[J]. Gut, 2021,70(4):761-774.
[28] Zhang H, Léveillé M, Courty E, et al. Differences in metabolic and liver pathobiology induced by two dietary mouse models of nonalcoholic fatty liver disease[J]. Am J Physiol Endocrinol Metab, 2020,319(5):E863-E876.
[29] Perakakis N, Joshi A, Peradze N, et al. The selective peroxisome proliferator-activated receptor gamma modulator chs-131 improves liver histopathology and metabolism in a mouse model of obesity and nonalcoholic steatohepatitis[J]. Hepatol Commun, 2020,4(9):1302-1315.
[30] Kristiansen M N, Veidal S S, Rigbolt K T, et al. Obese diet-induced mouse models of nonalcoholic steatohepatitis-tracking disease by liver biopsy[J]. World J Hepatol, 2016,8(16):673-684.
[31] Clapper J R, Hendricks M D, Gu G, et al. Diet-induced mouse model of fatty liver disease and nonalcoholic steatohepatitis reflecting clinical disease progression and methods of assessment[J]. Am J Physiol Gastrointest Liver Physiol, 2013,305(7):G483-G495.
[32] Gallage S, Avila J E B, Ramadori P, et al. A researcher's guide to preclinical mouse NASH models[J]. Nat Metab, 2022,4(12):1632-1649.
[33] Boland M L, Oró D, Tølbøl K S, et al. Towards a standard diet-induced and biopsy-confirmed mouse model of non-alcoholic steatohepatitis: impact of dietary fat source[J]. World J Gastroenterol, 2019,25(33):4904-4920.
[34] Madsen A N, Oró D, Madsen M R, et al. Development of hepatocellular carcinoma in the extended GAN diet-induced obese mouse model of nash with advanced fibrosis[J]. J Hepatol, 2022,77(S1):S389-S664.
[35] Wang H, Wu Y, Tang W. Methionine cycle in nonalcoholic fatty liver disease and its potential applications[J]. Biochem Pharmacol, 2022,200:115033.
[36] Vallianou N G, Kounatidis D, Psallida S, et al. The interplay between dietary choline and cardiometabolic disorders: a review of current evidence[J]. Curr Nutr Rep, 2024,13(2):152-165.
[37] Yu Y, Liu Y, An W, et al. STING-mediated inflammation in kupffer cells contributes to progression of nonalcoholic steatohepatitis[J]. J Clin Invest, 2019,129(2):546-555.
[38] Liu M T, Zhang Y, Xiang C G, et al. Methionine-choline deficient diet deteriorates DSS-induced murine colitis through disturbance of gut microbes and infiltration of macrophages[J]. Acta Pharmacol Sin, 2024,45(9):1912-1925.
[39] Alshawsh M A, Alsalahi A, Alshehade S A, et al. A comparison of the gene expression profiles of non-alcoholic fatty liver disease between animal models of a high-fat diet and methionine-choline-deficient diet[J]. Molecules, 2022,27(3):858.
[40] Itagaki H, Shimizu K, Morikawa S, et al. Morphological and functional characterization of non-alcoholic fatty liver disease induced by a methionine-choline-deficient diet in c57BL/6 mice[J]. Int J Clin Exp Pathol, 2013,6(12):2683-2696.
[41] Rinella M E, Green R M. The methionine-choline deficient dietary model of steatohepatitis does not exhibit insulin resistance[J]. J Hepatol, 40 (1):47-51.
[42] Fuchs C D, Radun R, Dixon E D, et al. Hepatocyte-specific deletion of adipose triglyceride lipase (adipose triglyceride lipase/patatin-like phospholipase domain containing 2) ameliorates dietary induced steatohepatitis in mice[J]. Hepatology, 2022,75(1):125-139.
[43] Rinella M E, Elias M S, Smolak R R, et al. Mechanisms of hepatic steatosis in mice fed a lipogenic methionine choline-deficient diet[J]. J Lipid Res, 2008,49(5):1068-1076.
[44] Ikawa-Yoshida A, Matsuo S, Kato A, et al. Hepatocellular carcinoma in a mouse model fed a choline-deficient, l-amino acid-defined, high-fat diet[J]. Int J Exp Pathol, 2017,98(4):221-233.
[45] Zhang J, Zang X, Lv J, et al. Changes in lipidomics, metabolomics, and the gut microbiota in CDAA-induced NAFLD mice after polyene phosphatidylcholine treatment[J]. Int J Mol Sci, 2023,24(2):1502
[46] Farrell G, Schattenberg J M, Leclercq I, et al. Mouse models of nonalcoholic steatohepatitis: toward optimization of their relevance to human nonalcoholic steatohepatitis[J]. Hepatology, 2019,69(5):2241-2257.
[47] Kodama Y, Kisseleva T, Iwaisako K, et al. C-JUN n-terminal kinase-1 from hematopoietic cells mediates progression from hepatic steatosis to steatohepatitis and fibrosis in mice[J]. Gastroenterology, 2009,137(4):1467-1477.
[48] Matsumoto M, Hada N, Sakamaki Y, et al. An improved mouse model that rapidly develops fibrosis in non-alcoholic steatohepatitis[J]. Int J Exp Pathol, 2013,94(2):93-103.
[49] Fengler V H, Macheiner T, Kessler S M, et al. Susceptibility of different mouse wild type strains to develop diet-induced NAFLD/AFLD-associated liver disease[J]. Plos One, 2016,11(5):e155163.
[50] Kawashita E, Ishihara K, Nomoto M, et al. A comparative analysis of hepatic pathological phenotypes in C57BL/6J and C57BL/6N mouse strains in non-alcoholic steatohepatitis models[J]. Sci Rep, 2019,9(1):204.
[51] Miller M J, Harding-Theobald E, DiBattista J V, et al. Progression to cirrhosis is similar among all ages in nonalcoholic fatty liver disease, but liver-related events increase with age[J]. Hepatol Commun, 2023,7(6):e0148
[52] Nestor J J, Parkes D, Feigh M, et al. Effects of alt-801, a GLP-1 and glucagon receptor dual agonist, in a translational mouse model of non-alcoholic steatohepatitis[J]. Sci Rep, 2022,12(1):6666.
[53] Li X, Lu Y, Liang X, et al. A new NASH model in aged mice with rapid progression of steatohepatitis and fibrosis[J]. PLoS One, 2023,18(5):e286257.
[54] Fontana L, Zhao E, Amir M, et al. Aging promotes the development of diet-induced murine steatohepatitis but not steatosis[J]. Hepatology, 2013,57(3):995-1004.
[55] Balakrishnan M, Patel P, Dunn-Valadez S, et al. Women have a lower risk of nonalcoholic fatty liver disease but a higher risk of progression vs men: a systematic review and meta-analysis[J]. Clin Gastroenterol Hepatol, 2021,19(1):61-71.
[56] Smati S, Polizzi A, Fougerat A, et al. Integrative study of diet-induced mouse models of NAFLD identifies pparα as a sexually dimorphic drug target[J]. Gut, 2022,71(4):807-821.
[57] Tian Y, Hong X, Xie Y, et al. 17β-estradiol (E2) upregulates the ERα/SIRT1/PGC-1α signaling pathway and protects mitochondrial function to prevent bilateral oophorectomy (OVX)-induced nonalcoholic fatty liver disease (NAFLD)[J]. Antioxidants (Basel), 2023,12(12):2100.